Archeus Technologies Inc. has obtained IND clearance from the FDA for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer.

Archeus Technologies Inc. and the Wisconsin Alumni Research Foundation (WARF) have entered into a strategic collaboration to advance ART-101, a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule, into clinical development for prostate cancer.